393 related articles for article (PubMed ID: 15327545)
1. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson CC; Kimball AB
Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
[TBL] [Abstract][Full Text] [Related]
2. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.
Berth-Jones J; Thompson J; Papp K;
Br J Dermatol; 2008 Aug; 159(2):407-12. PubMed ID: 18565187
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
4. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients.
Louden BA; Pearce DJ; Lang W; Feldman SR
Dermatol Online J; 2004 Oct; 10(2):7. PubMed ID: 15530297
[TBL] [Abstract][Full Text] [Related]
5. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
Carlin CS; Feldman SR; Krueger JG; Menter A; Krueger GG
J Am Acad Dermatol; 2004 Jun; 50(6):859-66. PubMed ID: 15153885
[TBL] [Abstract][Full Text] [Related]
6. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis.
Henseler T; Schmitt-Rau K
Int J Dermatol; 2008 Oct; 47(10):1019-23. PubMed ID: 18986347
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin for the treatment of plaque-type psoriasis.
Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
[TBL] [Abstract][Full Text] [Related]
9. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.
Berth-Jones J; Grotzinger K; Rainville C; Pham B; Huang J; Daly S; Herdman M; Firth P; Hotchkiss K
Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419
[TBL] [Abstract][Full Text] [Related]
10. Synchronous balneophototherapy is effective for the different clinical types of psoriasis.
Holló P; Gonzalez R; Kása M; Horváth A
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):578-81. PubMed ID: 16164712
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
12. A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser.
Housman TS; Pearce DJ; Feldman SR
J Dermatolog Treat; 2004 Apr; 15(2):94-7. PubMed ID: 15204159
[TBL] [Abstract][Full Text] [Related]
13. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
[TBL] [Abstract][Full Text] [Related]
14. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
Langley RG; Ellis CN
J Am Acad Dermatol; 2004 Oct; 51(4):563-9. PubMed ID: 15389191
[TBL] [Abstract][Full Text] [Related]
15. Application of machine vision to assess involved surface in patients with psoriasis.
Savolainen L; Kontinen J; Röning J; Oikarinen A
Br J Dermatol; 1997 Sep; 137(3):395-400. PubMed ID: 9349336
[TBL] [Abstract][Full Text] [Related]
16. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment.
Schäfer I; Hacker J; Rustenbach SJ; Radtke M; Franzke N; Augustin M
Eur J Dermatol; 2010; 20(1):62-7. PubMed ID: 19822480
[TBL] [Abstract][Full Text] [Related]
17. Physical and psychologic measures are necessary to assess overall psoriasis severity.
Kirby B; Richards HL; Woo P; Hindle E; Main CJ; Griffiths CE
J Am Acad Dermatol; 2001 Jul; 45(1):72-6. PubMed ID: 11423838
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
19. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
Reich K; Griffiths CE
Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
[TBL] [Abstract][Full Text] [Related]
20. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
